Profile of Prof. Dr. Markus Pfirrmann
Lead of RG Clinical Trials and Prognosis Research; Acting Deputy Director of the Department of Medical Biometry and of the IBE
Lead of RG Clinical Trials and Prognosis Research; Acting Deputy Director of the Department of Medical Biometry and of the IBE
1987–1993: Studied statistics at Ludwig Maximilian University in Munich
1993–1994: Master of Science in “Applied Stochastic Systems” at University College London
1995–1997: Research associate at the IBE, leading the international “Collaborative Prognostic Factors Project” to predict survival in patients with chronic myeloid leukemia (CML) undergoing treatment with interferon-alpha.
1997–1998: Project manager and lead biometrician for several clinical trials on CML at the BZT Biometric Center for Therapeutic Studies, Munich
1998–2007 Project manager and lead biometrician for several clinical trials on chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) at the GIS Society for Information Processing and Statistics in Medicine e.V.
In 2000, jointly with co-authors, received the Paul Martini Prize from the German Society for Medical Informatics, Biometrics, and Epidemiology (GMDS e.V.).
Since 2007, Project Manager and Lead Biometrician for several clinical trials on CML and AML at the IBE
2007: Ph.D. thesis on “The Development and Validation of a Prognostic Score for Patients with Chronic Myeloid Leukemia, Incorporating Cytogenetic Remission as a Time-Dependent Covariate”
In 2012, assumed sole responsibility for managing all new clinical trials within the Chair of “Medical Information Processing, Biometrics, and Epidemiology” and, as part of this, introduced the electronic data collection system “Marvin.”
Since 2016, Head of the “Clinical Trials and Prognosis Research” research group.
2016 Habilitation thesis on the topic “The Application of Advanced Statistical Methodology to Clinical Questions—Synergies in Joint Scientific Projects Between Clinicians and Statisticians”
2024 Appointed Adjunct Professor at the IBE
| Name of project | Description |
|---|---|
| CML V TIGER-Study | A prospective, randomized, open-label, multicenter therapeutic study comparing nilotinib with and without interferon as induction therapy, and nilotinib versus interferon as maintenance therapy for the treatment of chronic myeloid leukemia (CML). |
| DasaHIT-Study | A prospective, randomized, open-label, multicenter dasatinib dose-optimization study to evaluate the tolerability and efficacy of medication taken on 5 out of 7 days of the week versus daily dosing in patients with CML. |
| FASCINATION-Study | Prospective, non-randomized, open-label, multicenter study of deep molecular response in CML patients treated with a combination of an established tyrosine kinase inhibitor and asciminib. |
| TRACE-Study | A prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy of multi-specific T-cell infusion against chemo-refractory viral infections following allogeneic stem cell transplantation. |
| NAUT-Study | Prospective, open-label, multicenter registry study to investigate the feasibility of discontinuing therapy again in CML patients who relapsed after the first discontinuation of therapy but subsequently achieved deep remission following renewed nilotinib therapy lasting at least two years. |
| PONTrack-Study | Prospective, open-label, multicenter registry study on deep molecular response in CML patients who have received 2 years of ponatinib treatment. |
| CML-TFR-Registry | A registry for the prospective assessment of treatment-free molecular remission status in CML, with the aim of investigating prognostic factors. |
| International CML Genomics Alliance | Global genomic data to evaluate the clinical relevance of pathogenic variants at the time of diagnosis of CML in the chronic phase with regard to events such as the occurrence of BCR::ABL1 kinase domain mutations, disease progression, or death. |
| ESTIMATION-Study | Registry for the prospective assessment of molecular remission success in CML patients with the T315I mutation who are being treated with asciminib. |
| EURO-SKI-Study | Registry for prognostic research on the maintenance of molecular remission in CML patients following discontinuation of therapy. |
| ELN/EUTOS-Registry | A registry for prognostic research on prospectively enrolled CML patients treated predominantly with imatinib and their outcomes over the course of therapy. |